Belantamab Mafodotin Shows Promising Response in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated   in patients with heavily pretreated relapsed or refractory multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news